CD274 and breast carcinoma: The systematic implementation of combined PD-L1 and TILs analyses as a comprehensive immuno-oncological biomarker to select patients for PD-1/PD-L1 inhibitor–based immune-therapy in breast cancer patients should be strongly considered by industry and academia (Gonzalez-Ericsson et al., 2020).